DRUG

20.2901.98%
HY

Herbert Y. Meltzer

Member of the Scientific and Clinical Advisory Board

Dr. Herbert Y. Meltzer, also known as Herb, IPAP, M.D., NARSAD, is Member of the Scientific and Clinical Advisory Board of Acadia Pharmaceuticals Inc. (formerly known as Receptor Technologies, Inc.). He served as Member of Scientific Advisory Board of LB Pharmaceuticals Inc since September 2017 until 2024. He serves as Member of Scientific Advisory Board at Bright Minds Biosciences Inc. since May 2022. He serves as Medical Director of PrecisionMed, Inc. Prof. Meltzer serves as the President of the American College of Neuropsychopharmacology and Collegium International Neuro-psychopharmacolog. He is Professor of Psychiatry and Behavioral Sciences and Professor of Pharmacology and Physiology at the Feinberg School of Medicine Chicago. He is Director of the Translational Neuropharmacology Program at Northwestern University in Chicago, IL. He visiting Professor at the Soochow University School of Medicine in Suzhou, China. He served as Member of Advisory Board at Reviva Pharmaceuticals Holdings, Inc. He served as editor of Psychopharmacology: The Third Generation of Progress and co-editor of the ACNP journal, Neuropsychopharmacology and is a member of the editorial board of numerous scientific journals. Dr. Meltzer is the recipient of the Efron and Paul Hoch Awards of the ACNP, the Noyes Prize of the Commonwealth of Pennsylvania, the Edward J. Sachar Award from Columbia University, the Lieber Prize for Schizophrenia Research from NARSAD, the Stanley Dean Award for Research in Schizophrenia of the American College of Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Earl Sutherland Prize for Achievement in Research of Vanderbilt University (2004), the Research Prize of the American Psychiatric Association (2005) and the Grant Liddle Award for Clinical Research from Vanderbilt University (2008) and the Lifetime Achievement Award of the Winter Conference on Psychosis Research (2011). Dr. Meltzer’s research interests include the discovery, development and optimal utilization of clozapine and other novel pharmacologic treatments for schizophrenia and related disorders, including bipolar disorder, the causes and novel treatments for cognitive impairment in schizophrenia and bipolar disorder, the elucidation of the mechanism of action of antipsychotic and other psychotropic drugs, especially the role of 5-HT2A and 5-HT1A receptors, the development of genetic biomarkers for personalized medicine in psychiatry and the causes and prevention of suicide. His research interests include: the development of novel drugs for treatment and prevention of psychosis, depression, opioid abuse and age-associated cognitive impairment; behavioral and neurochemical studies of antipsychotic, antidepressant, cognitive improving and anti-suicide drugs; and genetic biomarkers. He received his BA with Distinction from Cornell University in 1958, an MA in Chemistry from Harvard University in 1959 and his MD from Yale University in 1963.

Positions